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ABSTRACT
OBJECTIVE
To investigate the efficacy and safety of 
antidepressants for back and osteoarthritis pain 
compared with placebo.
DESIGN
Systematic review and meta-analysis.
DATA SOURCES
Medline, Embase, Cochrane Central Register 
of Controlled Trials, CINAHL, International 
Pharmaceutical Abstracts, ClinicalTrials.gov, and the 
World Health Organization International Clinical Trials 
Registry Platform from inception to 15 November and 
updated on 12 May 2020.
ELIGIBILITY CRITERIA FOR STUDY SELECTION
Randomised controlled trials comparing the efficacy 
or safety, or both of any antidepressant drug with 
placebo (active or inert) in participants with low back 
or neck pain, sciatica, or hip or knee osteoarthritis.
DATA EXTRACTION AND SYNTHESIS
Two independent reviewers extracted data. Pain and 
disability were primary outcomes. Pain and disability 
scores were converted to a scale of 0 (no pain or 
disability) to 100 (worst pain or disability). A random 
effects model was used to calculate weighted mean 
differences and 95% confidence intervals. Safety (any 
adverse event, serious adverse events, and proportion 
of participants who withdrew from trials owing to 
adverse events) was a secondary outcome. Risk of 
bias was assessed with the Cochrane Collaboration’s 
tool and certainty of evidence with the grading of 
recommendations assessment, development and 
evaluation (GRADE) framework.
RESULTS
33 trials (5318 participants) were included. 
Moderate certainty evidence showed that serotonin-
noradrenaline reuptake inhibitors (SNRIs) reduced 
back pain (mean difference −5.30, 95% confidence 
interval −7.31 to −3.30) at 3-13 weeks and low 
certainty evidence that SNRIs reduced osteoarthritis 
pain (−9.72, −12.75 to −6.69) at 3-13 weeks. Very low 
certainty evidence showed that SNRIs reduced sciatica 
at two weeks or less (−18.60, −31.87 to −5.33) but 
not at 3-13 weeks (−17.50, −42.90 to 7.89). Low 
to very low certainty evidence showed that tricyclic 
antidepressants (TCAs) did not reduce sciatica at two 
weeks or less (−7.55, −18.25 to 3.15) but did at 3-13 
weeks (−15.95, −31.52 to −0.39) and 3-12 months 
(−27.0, −36.11 to −17.89). Moderate certainty 
evidence showed that SNRIs reduced disability from 
back pain at 3-13 weeks (−3.55, −5.22 to −1.88) and 
disability due to osteoarthritis at two weeks or less 
(−5.10, −7.31 to −2.89), with low certainty evidence 
at 3-13 weeks (−6.07, −8.13 to −4.02). TCAs and 
other antidepressants did not reduce pain or disability 
from back pain.
CONCLUSION
Moderate certainty evidence shows that the effect 
of SNRIs on pain and disability scores is small and 
not clinically important for back pain, but a clinically 
important effect cannot be excluded for osteoarthritis. 
TCAs and SNRIs might be effective for sciatica, but the 




Back pain (low back or neck pain with or without 
radicular symptoms) and osteoarthritis are leading 
causes of disability worldwide.1 The prevalence of 
low back pain and neck pain is 7.3% and 5.0%, 
respectively. Osteoarthritis related hip and knee 
symptoms affect 12% of the global population.2 3 In 
2016, back pain and osteoarthritis pain accounted 
for $214.5bn (£161.0bn; €177.0bn) in healthcare 
spending in the US, with the highest expenditure for 
back pain, among all health conditions.4
Prescriptions for antidepressants are increasing 
worldwide for a range of indications.5 Among 
drugs associated with dependence and withdrawal, 
antidepressants are the most commonly prescribed 
medicines in the UK, with more people prescribed 
antidepressants (7.2 million) than prescribed opioid 
analgesics (5.6 million).6 The use of antidepressants to 
treat pain, especially chronic pain, is also common—
antidepressants are the fourth most prescribed 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Antidepressants are widely used for the treatment of back pain (with and without 
radicular symptoms) and hip and knee osteoarthritis 
Most clinical practice guidelines recommend antidepressants for these 
conditions
Evidence supporting the use of antidepressants for back pain and hip and knee 
osteoarthritis is uncertain
WHAT THIS STUDY ADDS
Moderate certainty evidence shows that serotonin-noradrenaline reuptake 
inhibitors (SNRIs) offer a small, non-clinically relevant benefit for people with 
back pain and osteoarthritis
SNRIs and tricyclic antidepressants might provide clinically important benefits 
for sciatica, but the certainty of evidence is low to very low
Only SNRIs increased the risk of adverse events; however, the number of studies 
evaluating the safety of other antidepressant classes was small, trials were 
underpowered to detect harm, and the certainty of evidence ranged from low to 
very low
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medicine for low back pain in the US. More than one 
quarter of Americans with chronic low back pain are 
prescribed an antidepressant within three months 
of a first diagnosis.7 In Quebec, Canada, the tricyclic 
antidepressant (TCA) amitriptyline and its active 
metabolite nortriptyline are commonly prescribed 
for pain, representing 48.4% and 57.4% of all 
prescriptions for these antidepressants, respectively.8 
In the UK, 16% of prescriptions for antidepressants in 
children and adolescents are for pain, and from 2003 
to 2014 prescriptions for antidepressants in these 
age groups almost tripled.9 The widespread use of 
antidepressants for pain also occurs in middle income 
countries. Amitriptyline is widely used in primary care 
in South Africa, mostly for osteoarthritis. This accounts 
for just over a quarter of all amitriptyline prescribed.10
Antidepressants are endorsed by most (75%) 
clinical practice guidelines for low back pain11 and by 
two recently published osteoarthritis guidelines.12  13 
The American College of Physicians, for example, 
recommends the serotonin-noradrenaline reuptake 
inhibitor (SNRI) duloxetine for low back pain.14 The 
UK National Institute for Health and Care Excellence 
recommends amitriptyline or duloxetine as the 
preferred treatment for people with different forms of 
neuropathic pain, including back pain with radicular 
symptoms.15 Osteoarthritis guidelines, such as those 
from the Osteoarthritis Research Society International 
(OARSI) and the American College of Rheumatology 
recommend duloxetine for pain management.12 13 
In the OARSI guideline, the focus is on people with 
osteoarthritis who have concomitant depression 
or widespread pain, or both. Evidence supporting 
the use of antidepressants is, however, uncertain. 
Systematic reviews of antidepressants for back pain 
and osteoarthritis have either not included several 
published trials,16 17 considered only one type of 
antidepressant (eg, duloxetine),18 or failed to assess 
the certainty of evidence.18 None of the existing reviews 
included unpublished records from trial registries. 
Reliance on published data alone has been shown 
to overestimate the efficacy of drug interventions 
for pain.19 To close this gap in knowledge, we 
systematically investigated the efficacy and safety of 
antidepressants in people with back pain (including 
sciatica) or hip or knee osteoarthritis.
Methods
Data sources and searches
The review protocol was prospectively registered 
on PROSPERO (CRD42020158521) and our 
findings are reported according to the preferred 
reporting items for systematic reviews and meta-
analyses (PRISMA) guidelines.20 We searched 
Medline, Embase, Cochrane Central Register 
of Controlled Trials, CINAHL, International 
Pharmaceutical Abstracts, ClinicalTrials.gov, 
and the World Health Organization International 
Clinical Trials Registry Platform from inception 
to 15 November and updated the searches on 12 
May 2020 (supplemental file 1). Two authors (GEF, 
MOK) independently screened records by titles and 
abstracts, and two authors (GEF, JZ) read full texts of 
potentially eligible studies to determine eligibility 
(see supplemental file 2 for a list of excluded trials 
with reasons). Any disagreements were resolved by 
consensus.
Eligibility criteria
We included randomised controlled trials that 
compared any antidepressant drug with placebo in 
participants with back pain (neck or low back pain 
with or without radicular symptoms) or hip or knee 
osteoarthritis, or both. Symptoms of any duration 
were included. Trials including drug combinations 
were eligible if the treatment contrast between groups 
was antidepressant versus placebo. The placebo 
comparator could be active (a substance that has no 
known effect on pain but might mimic the adverse 
effects of antidepressants) or inert (a substance that 
is not thought to have a therapeutic or adverse effect). 
We included reports published in peer reviewed 
journals as well as unpublished data posted on 
trial registry platforms (ClinicalTrials.gov and WHO 
International Clinical Trials Registry Platform). Trials 
that reported data on either pain, disability, or adverse 
events were included. No restrictions were placed on 
language or publication date. We excluded studies that 
included participants with serious spinal conditions 
(eg,  fractures, cancer) and rheumatic conditions 
(eg, rheumatoid arthritis), unless these studies also 
included participants with back pain or hip or knee 
osteoarthritis, or a combination of these, and their 
data were reported separately. We considered studies 
to be eligible when participants received previous back 
or osteoarthritis surgery but excluded studies that 
evaluated immediate postoperative pain management 
(ie, surgery within past month). Abstracts from 
conferences were also excluded.
Data extraction
Two authors (GEF, JZ) independently extracted data. 
Whenever possible, for each outcome we extracted 
post-treatment means, standard deviations, and 
number of participants in each group. When post-
treatment scores were not reported, we extracted 
data according to the hierarchy of between group 
differences and corresponding 95% confidence 
intervals at follow-up and then pre-treatment to post-
treatment within group change scores. When a study 
did not report standard deviations, we used estimation 
methods recommended by the Cochrane handbook 
for systematic reviews of interventions.21 Cochrane’s 
RevMan calculator was used to estimate standard 
deviations.22 These methods were used to estimate 
standard deviations for pre-treatment to post-treatment 
within group change scores, and to estimate standard 
deviations for between group differences. Briefly, we 
used the standard error and number of participants 
in each group to estimate standard deviations from 
pre-treatment to post-treatment within group change 
scores. To estimate standard deviations from between 
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group differences, we used P values, number of 
participants, and between group mean differences to 
obtain standard errors and thus obtain the standard 
deviation. For crossover trials, we followed guidance 
from the Cochrane handbook21 and extracted data 
from the pre-crossover and post-crossover periods as 
if the trial were a parallel trial, as this is a conservative 
approach. When data were not available in the 
published manuscript, we sought and, when available, 
extracted data on safety from the trial registry.
Outcomes
The primary outcomes were pain intensity and 
disability. Adverse events were a secondary outcome. 
Adverse events included the number of participants 
who experienced any adverse event (as defined by 
each study), experienced any serious adverse event 
(as defined by each study), and withdrew because of 
adverse effects.
Risk of bias and certainty of evidence
Two reviewers (GEF, MOK) rated risk of bias of trials 
using the Cochrane Collaboration risk of bias tool.23 
Disagreements were resolved by consensus. We 
assessed the certainty of evidence using the grading 
of recommendations assessment, development 
and evaluation (GRADE) framework.24 Certainty of 
evidence refers to the confidence that the true effect 
lies in a particular range.25 The certainty of evidence 
was downgraded by one level if a serious flaw was 
present in the domains of limitations in study design, 
inconsistency, imprecision, and small study bias. We 
did not downgrade for indirectness because patients, 
interventions, and comparators were similar across 
comparisons (see supplemental file 3 for a description 
of the GRADE framework used). The certainty of 
evidence was then classified as high, moderate, low, or 
very low. High certainty means we are confident that the 
true effect lies close to that of the estimate of the effect. 
Moderate certainty means we are moderately confident 
in the effect estimate; the true effect is likely to be close 
to the estimate of the effect, but there is a possibility 
that it is substantially different. Low certainty means 
our confidence in the effect estimate is limited; the 
true effect might be substantially different from the 
estimate of the effect. Very low certainty means we 
have very little confidence in the effect estimate; the 
true effect is likely to be substantially different from the 
estimate of effect.25
Data synthesis and analysis
We classified follow-up times into two weeks or less, 
3-13 weeks, 3-12 months, and more than 12 months. 
In studies with multiple time points, we extracted data 
from the time point closest to two weeks and three, six 
and 12 months. When trials had multiple treatment 
groups, we divided the number of participants in the 
placebo group by the number of treatment groups. For 
dichotomous outcomes, both the number of events 
and the sample size were divided by the number of 
treatment groups.21
To facilitate the interpretation of our results, we 
converted pain and disability scores to a common 
0-100 scale, with 0 denoting no pain or disability and 
100 denoting the worst possible pain or disability. 
This was done because benchmarks for clinically 
important differences in pain and disability are 
expressed in points, usually on a 0-100 scale, and not 
in proportions of a standard deviation.26 27 Raw scores 
were thus expressed as a percentage of the maximum 
possible score on that scale, as done in previous 
systematic reviews.16 28 29 Supplemental files 4 and 5 
present details on the pain and disability measures 
used by studies, and conversion procedures. Mean 
differences (95% confidence intervals) were calculated 
for continuous outcome measures, and risk ratios (95% 
confidence intervals) were calculated for dichotomous 
outcomes. Statistical heterogeneity in each meta-
analysis was determined by means of the I2 test. A 
random effects model was used across all comparisons. 
We grouped antidepressants based on their drug class. 
A pooled between group mean difference of 10 points 
(on a 0-100 scale) was considered by us to be the 
threshold for the smallest worthwhile effect for pain 
and disability.30 Pooled mean differences between 
groups below this threshold were considered clinically 
unimportant. This threshold has been used in other 
reviews of drug treatments for back pain,17 31 32 and 
it is also the recommended threshold for pain and 
disability in osteoarthritis.33 34 We used funnel plots to 
test for small study effects when at least 10 trials were 
available within a comparison.21 The Egger’s test was 
used to investigate small study effects. For comparisons 
when a funnel plot was available, we downgraded the 
certainty of evidence when the Egger’s test result was 
significant (two tailed P<0.05). When a funnel plot 
was not available, we downgraded the certainty of 
evidence if more than 25% of the participants were 
from small studies (<100 participants in each arm).21 
For continuous outcomes, we calculated the mean 
difference between groups and the respective standard 
error in Comprehensive Meta-analysis V3 and entered 
these data in RevMan version 5.3 using the Generic 
inverse variance method to obtain forest plots. For 
dichotomous outcomes, we used the Mantel-Haenszel 
method in RevMan version 5.3.
Exploratory meta-regression
We performed meta-regression to explore the 
moderator effects of risk of bias (high risk of bias if 
at least one domain was classified as high risk of bias 
or more than half of the domains were classified as 
unclear), industry sponsor (yes or no), small study 
effects (<100 participants in each arm), depression 
listed as inclusion criteria (yes or no), and dose of 
antidepressant on pain. For this analysis we grouped 
all antidepressant classes together.
Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for the design of the study 
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owing to lack of funding to include them as partners 
in this review. No patients were asked to advise on 
interpretation or writing up of results. Results of this 
review will be disseminated to the relevant patient 
organisations.
Results
Overall, 2771 records were retrieved. Of these, 1930 
records were screened after removal of duplicates and 
1795 were excluded based on titles and abstracts. Of 
131 potentially relevant trials screened for eligibility, 
33 trials enrolling 5318 participants were included 
(fig 1). Most trials (n=28, 84.9%) used a parallel 
group design, whereas five (15.2%) used a crossover 
design with washout periods ranging from one week 
to two weeks.35-39 Fourteen trials were sponsored 
by industry,38 40-52 and sponsorship source was 
unclear in five trials.39 53-56 All but one trial reported 
data from participants with chronic pain.57 Only 
five trials restricted inclusion to participants with 
depression.45 53-55 58 In two other trials, between 40% 
and 50% of participants had depression.46 47 Others 
either excluded participants with depressive disorder 
or did not mention depression in the eligibility 
criteria. The median duration of the drug regimen 
was eight weeks. Six antidepressant drug classes were 
evaluated, including SNRIs (15 trials), TCAs (n=14 
trials), serotonin reuptake inhibitors (SSRIs, n=3), 
noradrenaline-dopamine reuptake inhibitors (NDRIs, 
n=1), serotonin antagonist and reuptake inhibitors 
(SARIs, n=1), and tetracyclic antidepressants (n=1). 
Supplemental file 6 provides details of the included 
trials.
For 26 of 33 trials, at least one domain was classified 
as high risk of bias (supplemental file 7). Twenty six 
trials were unclear in describing the methods used to 
conceal allocation and therefore were at unclear risk of 
selection bias. One trial was at high risk of performance 
bias owing to inadequate blinding of participants, and 
13 were at unclear risk of performance bias. One trial 
was at high risk of detection bias owing to inadequate 
blinding of participants, and another 12 trials were 
at unclear risk of detection bias. Eighteen trials were 
at high risk of attrition bias. Five and 14 trials were at 
high and unclear risk of reporting bias, respectively.
Back pain
Nineteen trials (23 comparisons) determined the 
efficacy of antidepressants for back pain. Of these, 16 
trials reported data for low back pain, one trial reported 
data for neck pain, and two trials reported data for low 
back and neck pain. Only one trial evaluated outcomes 
at 3-12 months. This trial investigated the efficacy of 
TCAs in participants with back pain. No trials evaluated 
outcomes at more than 12 months. Only pain outcomes 
were measured at two weeks or less of follow-up.
Moderate certainty evidence showed that SNRIs 
reduce pain at two weeks or less (mean difference 
−3.67, 95% confidence interval −5.91 to −1.42; three 
trials, 1068 participants) and 3-13 weeks (−5.30, 
−7.31 to −3.30; four trials, 1415 participants) (fig 2 and 
table 1). SNRIs were also shown to reduce disability at 
3-13 weeks (−3.55, −5.22 to −1.88; four trials, 1423 
participants; supplemental file 8 and table 2). The 
effect of SNRIs was small and below this review’s 
predetermined threshold of clinical importance. Low 
to very low certainty evidence showed that TCAs did 
not reduce pain at two weeks or less (−0.86, −5.40 
to 3.68; three trials, 145 participants), 3-13 weeks 
(−9.96, −21.50 to 1.58; seven trials, 591 participants), 
and 3-12 months (−7.81, −15.63 to 0.01; one trial, 
118 participants) (fig 3). Evidence ranging from low 
to very low certainty showed no benefit of a range of 
antidepressant classes, including SSRIs, tetracyclic 
antidepressants, SARIs, and NDRIs for pain and 
disability across follow-ups of two weeks or less, 3-13 
weeks, and 3-12 months.
A post hoc sensitivity analysis explored the effect 
of removing one trial from the pooled estimates for 
back pain.59 The participants in this trial had neck 
pain, received a dose of amitriptyline (5 mg/day) lower 
than the minimum dose recommended for pain relief 
(10-25 mg/day), and reported unexpectedly large 
improvements in pain and disability compared with 
other studies. That trial was also at high risk of attrition 
bias from lack of intention-to-treat analysis and a 
large proportion of participants lost to follow-up. The 
exclusion of this trial fully explained the heterogeneity 
for disability and heterogeneity was reduced from 
92% to 7% for pain. After excluding this trial, TCAs 
were found to significantly reduce pain (−5.37, −9.93 
to −0.80) and disability (−7.24, −11.25 to −3.22), but 
the effects were still small and below this review’s 
predetermined threshold for clinical importance.
Sciatica
Six trials reported data for sciatica. No trials evaluated 
outcomes at more than 12 months. Very low certainty 
evidence showed that SNRIs reduce pain at two 
weeks or less (−18.60, −31.87 to −5.33; one trial, 50 
participants) but not at 3-13 weeks (−17.50, −42.90 
to 7.89; three trials, 96 participants). Low to very low 
certainty evidence showed that TCAs did not reduce 
pain at two weeks or less (−7.55, −18.25 to 3.15; two 
trials, 94 participants) but did at 3-13 weeks (−15.95, 
−31.52 to −0.39; two trials, 114 participants) and 
3-12 months (−27.0, −36.11 to −17.89; one trial, 60 
participants) follow-ups (fig 4 and table 1). Tricyclic 
antidepressants did not reduce disability at two weeks 
or less and at 3-13 weeks but did at 3-12 months 
(supplemental file 9 and table 2).
Osteoarthritis
Eight trials (eight comparisons) evaluated the 
efficacy of antidepressants in participants with knee 
osteoarthritis. All trials were of SNRIs. None of the 
osteoarthritis trials included participants with hip 
osteoarthritis or evaluated outcomes at 3-12 months 
or more than 12 months. Moderate certainty evidence 
showed that SNRIs reduce pain at two weeks or less 
(−4.66, −6.28 to −3.04; four trials, 1328 participants) 
and low certainty evidence that SNRIs reduce pain 
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at 3-13 weeks (−9.72, −12.75 to −6.69; eight trials, 
1941 participants) (fig 5 and table 1). Low certainty 
evidence showed that SNRIs reduce disability at 
two weeks or less (−5.10, −7.31 to −2.89; one trial, 
353 participants) and 3-13 weeks (−6.07, −8.13 to 
−4.02; seven trials, 1810 participants) of follow-up 
(supplemental file 10 and table 2). The effect of SNRIs 
was small and below this review’s predetermined 
threshold of clinical importance—however, the lower 
limit of the confidence interval did contain clinically 
important effects for pain, but not for disability.
Safety
Twenty one trials (25 comparisons) enrolling 4107 
participants determined the safety of antidepressants 
for back pain and osteoarthritis. The type and reporting 
of adverse events varied noticeably across trials. 
Nausea was reported as the most prevalent adverse 
event in eight trials.43 44 50-52 56 60 61
Low certainty evidence showed that SNRIs increase 
the risk of any adverse event (62.5% v 49.7%; relative 
risk 1.23, 95% confidence interval 1.16 to 1.30; 13 
trials, 3447 participants), but not serious adverse 
events (1.6% v 1.3%; 1.12, 0.61 to 2.07; 10 trials, 
3309 participants) (supplemental files 11and 12 and 
table 3). Participants receiving SNRIs were also more 
likely to drop out of the study because of adverse events 
(12.4% v 5.3%; 2.16, 1.71 to 2.73) (supplemental 
file 13 and table 3). Supplemental files 14 to 17 
present funnel plots assessing small study effects 
in comparisons with more than 10 trials. Although 
other antidepressants, such as TCAs, SSRIs, tetracyclic 
antidepressants, NDRIs, and SARIs did not seem to 
increase the risk of adverse events or drop-outs owing 
to adverse events, the limited number of trials and 
large uncertainty around the risk estimates limit the 
ability of this systematic review and meta-analysis to 
determine the safety of these classes of antidepressants 
for back pain, sciatica, and osteoarthritis.
Exploratory sensitivity analyses
No interaction was found between risk of bias, study 
size, industry sponsorship, depression diagnosis, and 
daily dosage of duloxetine and treatment effects. The 
meta-regression analysis of dose-response effects of 
duloxetine in three different doses (20, 60, and 120 
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Fig 1 | Study flow diagram. RCTs=randomised controlled trials
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mg/day) showed no statistically significant difference 
between dose intensities (P=0.13). For all doses of 
duloxetine, point estimates of change in pain scores 
were below the threshold of clinical importance, 
although for 60 mg/day and 120 mg/day the lower 
limits of the confidence interval could suggest clinically 
important effects (supplemental file 18).
Discussion
We found moderate certainty evidence that SNRIs 
reduce pain and disability in people with back pain 
up to three months, but these effects are unlikely 
to be clinically important. For osteoarthritis, we 
found moderate certainty evidence that SNRIs 
reduce pain and disability up to three months, 
and a clinically important effect on pain cannot be 
excluded. Low certainty evidence showed that TCAs 
were ineffective for back pain and related disability. 
Tricyclic antidepressants and SNRIs might reduce 
pain in people with sciatica. In our review, only SNRIs 
statistically significantly increased the risk of adverse 
events. However, the number of studies evaluating the 
safety of other antidepressant classes was small, trials 
were underpowered to detect harm, and the certainty 
of evidence ranged from low to very low.
Strengths and weaknesses of this study
Our review has several strengths. We registered this 
review prospectively and performed a comprehensive 
literature search, including searches on clinical 
trial registries. We also complied with the PRISMA 
statement.20 The threshold for clinical importance 
(≥10 points on a 0-100 scale) used in our review was 
prespecified and has been widely used in the literature 
on back pain17 31 32 and osteoarthritis.33 34 We have also 
provided clinically interpretable effect estimates on a 
0-100 scale, whereas previous reviews had presented 
effect sizes in terms of units of standard deviation.17 18
SNRI (≤2 weeks)
  Skljarevski 2010 (duloxetine 60 mg/day)44
  Skljarevski 2009 (duloxetine 120 mg/day)43
  Konno 2016 (duloxetine 60 mg/day)40
  Skljarevski 2009 (duloxetine 60 mg/day)43
  Skljarevski 2009 (duloxetine 20 mg/day)43
Subtotal
Test for heterogeneity: τ2=0.00; χ2=2.08, df=4, P=0.72; I2=0%
Test for overall effect: Z=3.21, P=0.001
SNRI (3-13 weeks)
  Skljarevski 2010 (duloxetine 60 mg/day)44
  Skljarevski 2009 (duloxetine 60 mg/day)43
  Skljarevski 2010 (duloxetine 60 mg/day)42
  Skljarevski 2009 (duloxetine 120 mg/day)43
  Konno 2016 (duloxetine 60 mg/day)40
  Skljarevski 2009 (duloxetine 20 mg/day)43
Subtotal
Test for heterogeneity: τ2=0.00; χ2=3.67, df=5, P=0.60; I2=0%
Test for overall effect: Z=5.18, P<0.001
SSRI (≤ 2 weeks)
  Dickens 2000 (paroxetine 20 mg/day)45
Subtotal
Test for heterogeneity: Not applicable
Test for overall effect: Z=0.86, P=0.39
SSRI (3-13 weeks)
  Dickens 2000 (paroxetine 20 mg/day)45
  Atkinson 1999 (paroxetine 30 mg/day)72
  Atkinson 2007 (fluoxetine 16-514 ng/mL)71
Subtotal
Test for heterogeneity: τ2=0.00; χ2=0.19, df=2, P=0.91; I2=0%
Test for overall effect: Z=0.43, P=0.66
-6.70 (-12.11 to -1.29)
-4.70 (-12.48 to 3.08)
-3.30 (-6.24 to -0.36)
-1.60 (-9.30 to 6.10)
-0.90 (-8.86 to 7.06)
-3.67 (-5.91 to -1.42)
-8.20 (-13.69 to -2.71)
-6.30 (-14.00 to 1.40)
-6.00 (-10.16 to -1.84)
-5.80 (-13.58 to 1.98)
-4.70 (-7.74 to -1.66)
0.80 (-7.16 to 8.76)
-5.30 (-7.31 to -3.30)
-4.30 (-14.06 to 5.46)
-4.30 (-14.06 to 5.46)
0.00 (-9.84 to 9.84)
2.50 (-11.73 to 16.73)
3.50 (-9.83 to 16.83)
1.53 (-5.38 to 8.45)







(95% CI), IV, random
Mean difference

































































































Fig 2 | Mean differences (95% confidence intervals) for pain in trials assessing the efficacy of antidepressants for back pain. Pain is expressed 
on a 0-100 scale. Studies are ordered by effect size. SE=standard error; IV=inverse variance; SNRI=serotonin-noradrenaline reuptake inhibitors; 
SSRI=selective serotonin reuptake inhibitors; TCA=tricyclic antidepressants; NDRI=noradrenaline-dopamine reuptake inhibitors; SARI=serotonin 
antagonist and reuptake inhibitors
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Table 1 | Summary of findings and certainty of evidence for pain
Summary of findings Certainty of evidence
Certainty of 
evidence
No of participants 
(No of trials)
Mean difference (95% CI), 





 ≤2 weeks 1068 (3) −3.67 (−5.91 to −1.42) Downgraded* Not downgraded Not downgraded Not downgraded Moderate
 3-13 weeks 1415 (4) −5.30 (−7.31 to −3.30) Downgraded* Not downgraded Not downgraded Not downgraded Moderate
SSRI:
 ≤2 weeks 92 (1) −4.30 (−14.06 to 5.46) Downgraded* Not downgraded Not downgraded Downgraded§ Low
 3-13 weeks 170 (3) 1.53 (−5.38 to 8.45) Downgraded* Not downgraded Not downgraded Downgraded§ Low
TCAs:
 ≤2 weeks 145 (3) −0.86 (−5.40 to 3.68) Downgraded* Not downgraded Not downgraded Downgraded§ Low
 3-13 weeks 591 (7) −9.96 (−21.50 to 1.58) Downgraded* Downgraded† Not downgraded Downgraded§ Very low
 3-12 months 118 (1) −7.81 (−15.63 to 0.01) Downgraded* Not downgraded Not downgraded Downgraded§ Low
NDRI:
 3-13 weeks 44 (1) −1.0 (−12.23 to 10.23) Downgraded* Not downgraded Not downgraded Downgraded§ Low
SARI:
 3-13 weeks 40 (1) −5.40 (−22.94 to 12.14) Downgraded* Not downgraded Not downgraded Downgraded§ Low
Tetracyclic antidepressants:
 3-13 weeks 34 (1) −4.50 (−20.43 to 11.43) Downgraded* Not downgraded Not downgraded Downgraded§ Low
Sciatica
SNRI:
 ≤2 weeks 50 (1) −18.60 (−31.87 to −5.33) Downgraded* Not downgraded Downgraded‡ Downgraded§ Very low
 3-13 weeks 96 (3) −17.50 (−42.90 to 7.89) Downgraded* Downgraded† Downgraded‡ Downgraded§ Very low
TCAs:
 ≤2 weeks 94 (2) −7.55 (−18.25 to 3.15) Downgraded* Not downgraded Downgraded‡ Downgraded§ Very low
 3-13 weeks 114 (2) −15.95 (−31.52 to −0.39) Downgraded* Downgraded† Downgraded‡ Downgraded§ Very low
 3-12 months 60 (1) −27.0 (−36.11 to −17.89) Downgraded* Not downgraded Not downgraded Downgraded§ Low
Osteoarthritis
SNRI:
 ≤2 weeks 1328 (4) −4.66 (−6.28 to −3.04) Downgraded* Not downgraded Not downgraded Not downgraded Moderate
 3-13 weeks 1941 (8) −9.72 (−12.75 to −6.69) Downgraded* Downgraded† Not downgraded Not downgraded Low
SNRI=serotonin-noradrenaline reuptake inhibitors; SSRI=selective serotonin reuptake inhibitors; TCA=tricyclic antidepressants; NDRI=noradrenaline-dopamine reuptake inhibitors.
*Downgraded by one level because >25% of participants in this comparison were from studies at high risk of bias.
†Downgraded by one level because heterogeneity (I2) >50%.
‡Downgraded by one level because the limits of the 95% confidence interval were 20 points different to smallest worthwhile effect.
§Downgraded by one level owing to small study bias.
Table 2 | Summary of findings and certainty of evidence for disability
Summary of findings Certainty of evidence
Certainty of 
evidence
No. of participants 
(No of trials)
Mean difference 
(95% CI), 0-100 Study design Inconsistency Imprecision Small study effects
Back pain
SNRI:
 3-13 weeks 1423 (4) −3.55 (−5.22 to −1.88) Downgraded* Not downgraded Not downgraded Not downgraded Moderate
SSRI:
 3-13 weeks 1 (92) −2.20 (−8.08 to 3.68) Downgraded* Not downgraded Not downgraded Downgraded§ Low
TCAs:
 3-13 weeks 439 (4) −12.94 (−26.47 to 0.59) Downgraded* Downgraded† Downgraded‡ Downgraded§ Very low
 3-12 months 118 (1) −4.30 (−10.49 to 1.89) Downgraded* Not downgraded Not downgraded Downgraded§ Low
SARI:
 3-13 weeks 40 (1) 2.60 (−6.79 to 11.99) Downgraded* Not downgraded Not downgraded Downgraded§ Low
Sciatica
SNRI:
 3-13 weeks 8 (1) −4.40 (−19.92 to 11.12) Downgraded* Not downgraded Downgraded‡ Downgraded§ Very low
TCAs:
 ≤2 weeks 60 (1) −5.00 (−12.23 to 2.23) Downgraded* Not downgraded Not downgraded Downgraded§ Low
 3-13 weeks 116 (2) −8.42 (18.18 to 1.35) Downgraded* Downgraded† Not downgraded Downgraded§ Very low
 3-12 months 60 (1) −20.0 (−27.74 to −12.26) Downgraded* Not downgraded Downgraded‡ Downgraded§ Very low
Osteoarthritis
SNRI:
 ≤2 weeks 353 (1) −5.10 (−7.31 to −2.89) Downgraded* Not downgraded Not downgraded Not downgraded Moderate
 3-13 weeks 1810 (7) −6.07 (−8.13 to −4.02) Downgraded* Downgraded† Not downgraded Not downgraded Low
SNRI=serotonin-noradrenaline reuptake inhibitors; SSRI=selective serotonin reuptake inhibitors; TCA=tricyclic antidepressants; NDRI=noradrenaline-dopamine reuptake inhibitors.
*Downgraded by one level because >25% of participants in this comparison were from studies at high risk of bias.
†Downgraded by one level because heterogeneity (I2) >50%.
‡Downgraded by one level because the limits of the 95% confidence interval were 20 points different to smallest worthwhile effect.
§Downgraded by one level owing to small study bias.
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Our review has limitations. Uncertainty in the effects 
for sciatica and safety outcomes was noticeable. Also, 
we were not able to explore a dose-response relation 
for most antidepressants because of the low number 
of studies and varied doses. Nevertheless, we were 
able to conduct such an analysis for duloxetine (14 
trials) and found that 60 mg/day produced similar 
effects on pain to 120 mg/day. Finally, although we 
searched two comprehensive clinical trial registries 
(ClinicalTrials.gov and WHO International Clinical 
Trials Registry Platform), we might have missed trials 
that were conducted before these registries became 
active (2000 for ClinicalTrials.gov) and therefore 
were not registered. We identified two trials in these 
registries that had already been completed but without 
results available.62 63 As the authors did not reply to 
our requests for data, we cannot completely rule out 
selective reporting or publication bias.
Evidence update
Our review updates the evidence for back pain, 
sciatica, and osteoarthritis. For example, we included 
25 trials (n=2955 participants) for back pain and 
sciatica, whereas the most recent review included 
TCAs (≤2 weeks)
  Hameroff 1985 (doxepin 300 mg/day)55
  Jenkins 1976 (imipramine 75 mg/day)47
  Schliessbach 2018 (imipramine 75 mg/day)36
Subtotal
Test for heterogeneity: τ2=0.00; χ2=0.68, df=2, P=0.71; I2=0%
Test for overall effect: Z=0.37, P=0.71
TCAs (3-13 weeks)
  Maarrawi 2018 (amitriptyline 5 mg/day)59
  Hameroff 1985 (doxepin 300 mg/day)55
  Atkinson 1998 (nortriptyline 100 mg/day)73
  Gould 2020 (desipramine 15-65 ng/mL)69
  Atkinson 2007 (desipramine 5-242 ng/mL)71
  Jenkins 1976 (imipramine 75 mg/day)47
  Urquhart 2018 (amitriptyline 25 mg/day)70
Subtotal
Test for heterogeneity: τ2=208.82; χ2=72.79, df=6, P<0.001; I2=92%
Test for overall effect: Z=1.69, P=0.09
TCAs (3-12 months)
  Urquhart 2018 (amitriptyline 25 mg/day)70
Subtotal
Test for heterogeneity: Not applicable
Test for overall effect: Z=1.96, P=0.05
NDRI (3-13 weeks)
  Katz 2005 (bupropion 300 mg/day)38
Subtotal
Test for heterogeneity: Not applicable
Test for overall effect: Z=0.17, P=0.86
SARI (3-13 weeks)
  Goodkin 1990 (trazodone 600 mg/day)46
Subtotal
Test for heterogeneity: Not applicable
Test for overall effect: Z=0.60, P=0.55
Tetracyclic antidepressants (3-13 weeks)
  Atkinson 1999 (maprotiline 150 mg/day)72
Subtotal
Test for heterogeneity: Not applicable
Test for overall effect: Z=0.55, P=0.58    
-4.60 (-15.36 to 6.16)
-3.00 (-21.09 to 15.09)
0.20 (-5.01 to 5.41)
-0.86 (-5.40 to 3.68)
-27.80 (-31.05 to -24.55)
-18.10 (-31.72 to -4.48)
-7.90 (-17.07 to 1.27)
-6.00 (-19.01 to 7.01)
-4.00 (-17.90 to 9.90)
-2.00 (-18.64 to 14.64)
-1.10 (-7.86 to 5.66)
-9.96 (-21.50 to 1.58)
-7.81 (-15.63 to 0.01)
-7.81 (-15.63 to 0.01)
-1.00 (-12.23 to 10.23)
-1.00 (-12.23 to 10.23)
-5.40 (-22.94 to 12.14)
-5.40 (-22.94 to 12.14)
-4.50 (-20.43 to 11.43)
-4.50 (-20.43 to 11.43)







(95% CI), IV, random
Mean difference


































































































Fig 3 | Mean differences (95% confidence intervals) for pain in trials assessing the efficacy of antidepressants for back pain. Pain is expressed on 
a 0-100 scale. Studies are ordered by effect size. SE=standard error; IV=inverse variance; TCA=tricyclic antidepressants; NDRI=noradrenaline-
dopamine reuptake inhibitors; SARI=serotonin antagonist and reuptake inhibitors
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16 trials.17 Our findings are in accordance with those 
from a previous review of drug treatments for chronic 
low back pain, which found TCAs and SSRIs to be 
ineffective and SNRIs to be effective, although the 
effects were small.17 Our safety analyses showed that 
SNRIs statistically significantly increased the risk of 
any adverse event. The increased risk of adverse events 
with SNRIs had already been described in a review of 
osteoarthritis18 and chronic pain64 but not chronic low 
back pain.17
For this review we pooled data for TCAs and SNRIs 
for sciatica. Across pain and disability outcomes, TCAs 
were effective in three of six estimates, whereas SNRIs 
were effective in one of four estimates. In instances 
when these drugs were more effective than placebo, 
the effects exceeded our prespecified threshold for 
clinical importance. However, these estimates were 
based on less certain evidence. The low to very low 
certainty of evidence described in our review contrasts 
with a recent review of drug treatment for neuropathic 
pain in adults, which recommends TCAs and SNRIs as 
preferred treatment for people with neuropathic pain 
based on strong evidence.65
Our review also updates the evidence for 
osteoarthritis. We pooled data from eight osteoarthritis 
trials whereas a previous review only pooled five 
trials.18 We also explored the effect of dose on treatment 
effect estimates for back pain and osteoarthritis. We 
showed that the effects of duloxetine (an SNRI) were 
similar regardless of whether the dose used in the trials 
was 20, 60, or 120 mg/day.
Meaning of the study
Although the observed effect of SNRIs in reducing back 
pain and related disability was statistically significant, 
the magnitude of such effects was too small to be 
considered clinically important. Despite all the studies 
examining the effects of SNRIs for back pain being 
sponsored by industry,40 42-44 the confidence intervals 
around the effect estimate were narrow enough and 
did not include clinically important benefits, which 
further strengthens our confidence in the results.
SNRI (≤2 weeks)
  Schukro 2016 (duloxetine 120 mg/day)35  
Subtotal
Test for heterogeneity: Not applicable
Test for overall effect: Z=2.75, P=0.006
SNRI (3-13 weeks)
  Marks 2014 (milnacipran 100 mg/day)41
  Schukro 2016 (duloxetine 120 mg/day)35
  NCT01225068 2014 (milnacipran 100 mg/day)61
Subtotal
Test for heterogeneity: τ2=374.82; χ2=8.53, df=2, P=0.01; I2=77%
Test for overall effect: Z=1.35, P=0.18
TCAs (≤2 weeks)
  Vanelderen 2015 (amitriptyline 25 mg/day)60
  Pirbudak 2003 (amitriptyline 10-50 mg/day)57
Subtotal
Test for heterogeneity: τ2=27.83; χ2=1.82, df=1, P=0.18; I2=45%
Test for overall effect: Z=1.38, P=0.17
TCAs (3-13 weeks)
  Pirbudak 2003 (amitriptyline 10-50 mg/day)57
  Khoromi 2007 (nortriptyline 100 mg/day)37
Subtotal
Test for heterogeneity: τ2=91.12; χ2=3.47, df=1, P=0.06; I2=71%
Test for overall effect: Z=2.01, P=0.04
TCAs (3-12 months)
  Pirbudak 2003 (amitriptyline 10-50 mg/day)57
Subtotal
Test for heterogeneity: Not applicable
Test for overall effect: Z=5.81, P<0.001
-18.60 (-31.87 to -5.33)
-18.60 (-31.87 to -5.33)
-46.10 (-78.18 to -14.02)
-20.00 (-35.01 to -4.99)
6.50 (-13.37 to 26.37)
-17.50 (-42.90 to 7.89)
-14.10 (-27.23 to -0.97)
-3.00 (-12.33 to 6.33)
-7.55 (-18.25 to 3.15)
-23.00 (-32.11 to -13.89)
-7.00 (-21.15 to 7.15)
-15.95 (-31.52 to -0.39)
-27.00 (-36.11 to -17.89)
-27.00 (-36.11 to -17.89)







(95% CI), IV, random
Mean difference






































































Fig 4 | Mean differences (95% confidence intervals) for pain in trials assessing the efficacy of antidepressants for sciatica. Pain is expressed on 
a 0-100 scale. Studies are ordered by effect size. SE=standard error; IV=inverse variance; SNRI=serotonin-noradrenaline reuptake inhibitors; 
SSRI=selective serotonin reuptake inhibitors; TCA=tricyclic antidepressants; NDRI=noradrenaline-dopamine reuptake inhibitors; SARI=serotonin 
antagonist and reuptake inhibitors
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Caution is needed in interpreting our findings for 
sciatica. All sciatica trials were small, had imprecise 
estimates, and were at high risk of bias, which reduced 
the certainty of evidence to low and very low. This level 
of uncertainty indicates that the true estimate of effect of 
TCAs and SNRIs for sciatica is likely to be substantially 
different from what we estimated in our review.25
For osteoarthritis, although the point estimate 
was below our prespecified threshold of clinical 
importance, the lower limit of the confidence interval 
contains clinically important effects at 3-13 weeks, 
but not at two weeks or less. Therefore, a clinically 
important benefit of SNRI in people with osteoarthritis 
cannot be excluded.66 Six out of eight trials that 
SNRI (≤2 weeks)
  Uchio 2018 (duloxetine 60 mg/day)48
  Chappell 2009 (duloxetine 60-120 mg/day)50
  Chappell 2011 (duloxetine 60 mg/day)51
  Frakes 2011 (duloxetine 120 mg/day)52 
Subtotal
Test for heterogeneity: τ2=0.00; χ2=2.55, df=3, P=0.47; I2=0%
Test for overall effect: Z=5.65, P<0.001
SNRI (3-13 weeks)
  NCT01510457 2012 (milnacipran 200 mg/day)56
  Uchio 2018 (duloxetine 60 mg/day)48
  Abou-Raya 2012 (duloxetine 60 mg/day)58
  Chappell 2009 (duloxetine 60-120 mg/day)50
  Frakes 2011 (duloxetine 120 mg/day)52
  Chappell 2011 (duloxetine 60 mg/day)51
  Wang 2017 (duloxetine 60 mg/day)49
  Tetreault 2016 (duloxetine 60 mg/day)74
Subtotal
Test for heterogeneity: τ2=11.18; χ2=22.04, df=7, P=0.003; I2=68%
Test for overall effect: Z=6.29, P<0.001
-6.00 (-8.49 to -3.51)
-5.00 (-9.29 to -0.71)
-4.20 (-9.55 to 1.15)
-3.00 (-5.76 to -0.24)
-4.66 (-6.28 to -3.04)
-31.00 (-46.48 to -15.52)
-12.90 (-16.21 to -9.59)
-12.00 (-17.92 to -6.08)
-9.50 (-14.09 to -4.91)
-9.10 (-12.14 to -6.06)
-8.40 (-13.65 to -3.15)
-5.00 (-8.00 to -2.00)
-3.00 (-14.41 to 8.41)
-9.72 (-12.75 to -6.69)







(95% CI), IV, random
Mean difference












































































Fig 5 | Mean differences (95% confidence intervals) for pain in trials assessing the efficacy of antidepressants for osteoarthritis. Pain is expressed 
on a 0-100 scale. Studies are ordered by effect size. SE=standard error; IV=inverse variance; SNRI=serotonin-noradrenaline reuptake inhibitors; 
SSRI=selective serotonin reuptake inhibitors; TCA=tricyclic antidepressants; NDRI=noradrenaline-dopamine reuptake inhibitors; SARI=serotonin 
antagonist and reuptake inhibitors
Table 3 | Summary of findings and quality of evidence for safety









 SNRI 62.5/49.7 (13) 1.23 (1.16 to 1.30) Downgraded* Not downgraded Downgraded‡ Not downgraded Low
 SSRI 67.9/66.6 (2) 1.53 (0.19 to 12.61) Not downgraded Downgraded† Downgraded‡ Downgraded§ Very low
 TCAs 22.4/13.2 (8) 1.49 (0.95 to 2.34) Not downgraded Not downgraded Downgraded‡ Downgraded§ Low
 Tetracyclic antidepressants 90/93.8 (1) 0.96 (0.79 to 1.16) Downgraded* Not downgraded Not downgraded Downgraded§ Low
 NDRI 40/14.3 (1) 2.80 (1.30 to 6.02) Downgraded* Not downgraded Downgraded‡ Not downgraded Low
Serious adverse events:
 SNRI 1.6/1.3 (10) 1.12 (0.61 to 2.07) Downgraded* Not downgraded Downgraded‡ Not downgraded
 TCAs 2.6/0 (1) 2.62 (0.11 to 62.10) Downgraded* Not downgraded Downgraded‡ Downgraded§ Very low
 NDRI 4/2 (1) 1.96 (0.18 to 20.92) Downgraded* Not downgraded Downgraded‡ Downgraded§ Very low
 SARI 13.6/15 (1) 0.91 (0.21 to 4.0) Downgraded* Not downgraded Downgraded‡ Downgraded§ Very low
Risk of drop-out owing to adverse events:
 SNRI 12.4/5.3 (12) 2.16 (1.71 to 2.73) Downgraded* Not downgraded Not downgraded Not downgraded Moderate
 SSRI 17/6.5 (2) 2.36 (0.39 to 14.28) Downgraded* Not downgraded Downgraded‡ Downgraded§ Very low
 TCAs 10.8/4.6 (11) 1.48 (0.88 to 2.50) Downgraded* Not downgraded Downgraded‡ Not downgraded Low
 NDRI 6/0 (1) 6.86 (0.36 to 129.48) Downgraded* Not downgraded Downgraded‡ Downgraded§ Very low
 SARI 13.6/5 (1) 2.73 (0.31 to 24.14) Downgraded* Not downgraded Downgraded‡ Downgraded‡ Very low
 Tetracyclic antidepressants 17.6/5.5 (1) 3.18 (0.41 to 24.39) Downgraded* Not downgraded Downgraded‡ Downgraded§ Very low
SNRI=serotonin-noradrenaline reuptake inhibitors; SSRI=selective serotonin reuptake inhibitors; TCA=tricyclic antidepressants; NDRI=noradrenaline-dopamine reuptake inhibitors.
*Downgraded by one level because >25% of participants in this comparison were from studies at high risk of bias.
†Downgraded by one level because the 95% confidence interval include appreciable harm (ie, 95% confidence interval >1.25).
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investigated the efficacy of SNRI for osteoarthritis were 
also sponsored by industry.48-52 58
Participants with a diagnosis of depression did 
not benefit more from antidepressants for pain 
than those without depression. In both subgroups, 
improvements were below the threshold for clinically 
important effects. Furthermore, none of the trials that 
contributed data for the subgroup with depression 
were for osteoarthritis. The 2019 OARSI guideline 
recommends antidepressants (duloxetine) for knee 
osteoarthritis comorbid with depression or widespread 
pain disorders, or both.12 Some of the trials included 
in our review explored the indirect effect of duloxetine 
on depression and its role in mediating the effect on 
pain with path analysis.40 50 51 However, these trials 
excluded participants with major depressive disorder, 
and participants had low average scores (around 5 
points51) on the Beck depression inventory II, which 
were within the minimal range and below the proposed 
thresholds for diagnosing depression.67
How this study could promote better decisions
The UK68 and US14 guidelines for back pain provide 
conflicting recommendations on use of SNRIs. 
Our review shows that although these medicines 
are effective, the effect is small and unlikely to be 
considered clinically important by most patients. Our 
review also showed that about two thirds of patients 
using SNRIs experience adverse events. We would 
encourage clinicians to share all this information 
about SNRIs with patients to allow them to make an 
informed decision.
The low to very low certainty of evidence does not 
allow any firm recommendations in favour or against 
other classes of antidepressants, such as SSRIs, NDRIs, 
SARIs, and tetracyclic antidepressants for back pain. 
Nevertheless, our review provides some evidence that 
neither of these antidepressant classes are effective for 
back pain and therefore should not be used.
Current guidelines for neuropathic pain recommend 
antidepressants such as duloxetine (SNRI) and 
amitriptyline (TCA) as preferred treatment.15 In our 
review, despite the potentially clinically important 
benefits of SNRIs and TCAs for sciatica observed in 
some comparisons, the low to very low certainty of 
evidence and the lack of efficacy across several time 
points for pain and disability mean that evidence is 
insufficient to confidently guide the use of these drugs 
for sciatica.
Unanswered questions and future research
Large, definitive trials free of industry ties are urgently 
needed to evaluate the efficacy of antidepressants. In 
our review, all but one trial59 with sample sizes of more 
than 100 participants in each group were sponsored by 
industry. New trials will be particularly relevant when 
testing the efficacy of TCAs and SNRIs in people with 
sciatica, where clinically important benefits might 
exist; and in osteoarthritis, where clinically important 
benefits cannot be excluded but most of the data come 
from industry sponsored trials.48-52 58
The long term effects of antidepressants prescribed 
for chronic pain conditions is not well known. Trials 
of chronic pain generally measure safety outcomes 
for a limited time (3-35 weeks)64 and therefore do 
not capture long term effects known to affect those 
taking antidepressants, such as severe withdrawal 
symptoms.6
Conclusions
Moderate certainty evidence shows that the effect of 
SNRIs on pain and disability scores is small and not 
clinically important for back pain, but a clinically 
important effect cannot be excluded for osteoarthritis. 
Tricyclic antidepressants and SNRIs might be effective 
for sciatica, but the certainty of evidence ranged from 
low to very low. The risk of adverse events but not 
serious adverse events is slightly increased with SNRIs, 
although the certainty of the evidence was low. Large, 
definitive randomised trials that are free of industry 
ties are urgently needed to resolve uncertainties 
about the efficacy of antidepressants for sciatica and 
osteoarthritis highlighted by this review.
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